Abstract:Abstract BACKGROUND AND AIMS Sarcopenia is common in chronic kidney disease (CKD) and is associated with increased mortality and morbidity. Sarcopenia in CKD can be defined as a decreased muscle mass, mainly due to the catabolic state caused by the uremic environment. Malnutrition and inflammation are also common in sarcopenic patients. In this study, we aimed to investigate the prevalence of sarcopenia defined as low muscle mass determined by Psoas Muscle Index (PMI) in waitlisted end-stage renal disease (ESRD) patients and its association between ‘Prognostic Nutritional Index (PNI)’, ‘C-reactive protein (CRP) to Albumin Ratio (CAR)’ and mortality. METHOD ESRD patients registered to national kidney transplant waiting list and had abdomen CT at admission were included in the study. Kidney donor candidates were constituted as healthy controls. PMI (cm2/m2) were calculated by proportioning the psoas muscle area detected in the abdomen CT with the square of the height. The PMI of the controls at the fifth percentile according to gender was accepted as the limit value for sarcopenia. PNI and CAR were calculated using albumin, CRP and absolute lymphocyte count. The associations between PMI, PNI, CAR and all-cause mortality were investigated. RESULTS A total of 162 ESRD patients and 87 age matched healthy controls were included in the study. The mean age of the patients was 44.7 ± 14.2 years and follow-up time was 3.37 (0.35–9.60) years. The mean PMI were similar between the groups (5.24 ± 1.71 versus 5.48 ± 1.87 cm2/m2 P = 0.302). While prevalence of sarcopenia (16.7% versus 3.4%, P = 0.002) and CAR [1.47 (0.12–37.10) versus 0.74 (0.21–10.20), P < 0.001] was higher; PNI [40 (20.4–52.2) versus 44 (36.1–53.0), P < 0.001] was lower in ESRD patients than controls. When ESRD patients compared according to sarcopenia PMI [3.45 ± 0.9 versus 5.59 ± 1.6, P < 0.001] and PNI [39 (20.4–51) versus 41 (23–52.2), P = 0.005] was significantly lower and CAR [2.03 (0.28–34.65) versus 1.28 (0.12–37.1), P = 0.041] was higher in sarcopenic ESRD group than non-sarcopenic ESRD group (Table 1). In the correlation analysis, PMI was positively correlated with PNI (r = 0.246, P = 0.002), no correlated with CAR (r = −0.061, P = 0.445). In the follow-up, 67 waitlisted patients had been transplanted. In the five-year survival analysis, the non-sarcopenic transplant group [95% CI: 4.612–5.123 versus 95% CI: 2.721–5.413, P = 0.001] had better survival than sarcopenic transplant group (Figure 1). Mortality rates were similar in both sarcopenic transplant group and non-sarcopenic-non-transplant group. Multivariate regression analysis showed that sarcopenia (HR: 10.277, 95% CI: 3.912–27.000, P < 0.001), not having a transplant (HR: 3.949, 95% CI: 1.301–11.993, P = 0.015), low PNI (HR: 3.532, 95% CI: 1.303–9.574, P = 0.013) and duration of renal replacement therapy (HR: 1.009, 95% CI: 1.002–1.015, P = 0.008) were independent risk factors for mortality in all ESRD group. CONCLUSION In this study we observed that sarcopenia, as defined by low muscle mass, is almost seen five times more frequent in ESRD patients than controls and positively correlated with PNI. Sarcopenia is an independent risk factor for mortality in waitlisted patients.

Sarcopenia as a predictor of mortality in kidney transplant recipients: A 5-year prospective cohort study with propensity score matching

Computed Tomography-Assessed Sarcopenia Predicts Mortality in Kidney Transplant Candidates.

MO956: Sarcopenia Predicts Mortality in Renal Transplant Candidates

Assessing Patients beyond the Simple Optics of BMI: The Concomitant Role of Sarcopenia and BMI in Predicting Kidney Transplant Outcomes

Presence of Sarcopenia before Kidney Transplantation Is Associated with Poor Outcomes

Effect of pretransplant sarcopenia on patient and graft outcomes in solid organ transplant recipients: A systematic review and meta-analysis

Sarcopenia is associated with survival in patients awaiting kidney transplant

Prevalence and clinical impact of sarcopenia in liver transplant recipients: A meta-analysis

Association of sarcopenia with mortality and end‐stage renal disease in those with chronic kidney disease: a UK Biobank study

Study of Post-Kidney Transplantation Parietal Complications and Presarcopenia

Prognostic Value of Sarcopenia in Survivors of Hematological Malignances Undergoing a Hematopoietic Stem Cell Transplantation: a Systematic Review and Meta-Analysis

Validity of computed tomography defined body composition as a prognostic factor for functional outcome after kidney transplantation

Intake of polyunsaturated fatty acids and ω-3 are protective factors for sarcopenia in kidney transplant patients

Sarcopenic obesity is associated with adverse outcomes after kidney transplantation: a retrospective cohort study

Sarcopenic obesity and its relation with muscle quality and mortality in patients on chronic hemodialysis

Impact of Sarcopenia on the Survival of Patients Undergoing Liver Transplantation for Decompensated Liver Cirrhosis

Sarcopenia Defined by Psoas Muscle Index Independently Predicts Long-Term Survival after Living Donor Liver Transplantation in Male Recipients

#3007 Association between sarcopenia and clinical outcomes in patients on maintenance hemodialysis

Prognostic value of sarcopenia defined by the Sarcopenia Definitions and Outcomes Consortium criteria in patients with heart failure

Sarcopenia Predicts Prognosis of Patients with Renal Cell Carcinoma: A Systematic Review and Meta-Analysis

Use of Skeletal Muscle Index as a Predictor of Wait‐List Mortality in Patients With End‐Stage Liver Disease